DDInter1055 DDInter1863
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common liver fluke” or “the sheep liver fluke” or by _Fasciola gigantica_, another helminth. These parasites can infect humans following ingestion of larvae in contaminated water or food. Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. This drug is currently the only FDA-approved drug for individuals with fascioliasis, which affects 2.4 million people worldwide.[A174988,L5452]
Levofloxacin {u} (Compound) resembles {v} (Compound) Gemifloxacin
Gemifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triclabendazole
Levofloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Sparfloxacin {u} may lead to a major life threatening interaction when taken with {v} Triclabendazole
Levofloxacin {u} (Compound) resembles {v} (Compound) Gatifloxacin
Gatifloxacin {u} may lead to a major life threatening interaction when taken with {v} Triclabendazole
Levofloxacin {u} (Compound) resembles {v} (Compound) Gemifloxacin
Gemifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Triclabendazole
Levofloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Sparfloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Triclabendazole
Levofloxacin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Triclabendazole
Levofloxacin {u} (Compound) resembles {v} (Compound) Moxifloxacin
Moxifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Triclabendazole
Levofloxacin {u} (Compound) resembles {v} (Compound) Gemifloxacin
Gemifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triclabendazole
Levofloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Sparfloxacin {u} may lead to a major life threatening interaction when taken with {v} Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triclabendazole
Levofloxacin {u} (Compound) resembles {v} (Compound) Gatifloxacin
Gatifloxacin {u} may lead to a major life threatening interaction when taken with {v} Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triclabendazole
Levofloxacin (Compound) resembles Gemifloxacin (Compound) and Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Levofloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may lead to a major life threatening interaction when taken with Triclabendazole
Levofloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may lead to a major life threatening interaction when taken with Triclabendazole
Levofloxacin (Compound) resembles Gemifloxacin (Compound) and Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Levofloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Levofloxacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Levofloxacin (Compound) resembles Moxifloxacin (Compound) and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Levofloxacin (Compound) resembles Gemifloxacin (Compound) and Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Levofloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may lead to a major life threatening interaction when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Levofloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may lead to a major life threatening interaction when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole